Lymphoma Clinical Trials at the Mario Lemieux Center for Blood Cancers

This Phase 2 trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment or that has returned after a period of improvement. Onalespib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.

This randomized Phase 3 trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.

This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.

Principal Investigator: Alison Sehgal, MD
Co-Investigators: Kathleen Dorritie, MD, Warren Shlomchik, MD
Sponsor: Kite, a Gilead Company

View eligibility criteria and the full trial at ClinicalTrials.gov.

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment. Juno Therapeutics Inc. is the sponsor of this study.

Principal Investigator: Alison Sehgal, MD
Co-Investigators: Kathleen Dorritie, MD; Warren D. Shlomchik, MD

View eligibility criteria and the full trial description at ClinicalTrials.gov.

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 randomized part to assess JCAR017 monotherapy treatment versus standard of care. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: Juno Therapeutics, Inc.

View eligibility criteria and the full trial at ClinicalTrials.gov.

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Principal Investigator: Alison Sehgal, MD

Sponsor: Juno Therapeutics, Inc.

View eligibility criteria and the full trial description at ClinicalTrials.gov.

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory DLBCL.

Principal Investigator: Kathleen Dorritie, MD

Sponsor: Kite, A Gilead Company

View eligibility criteria and the full trial description at ClinicalTrials.gov.